Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab with Gemcitabine and Cisplatin in Advanced NSCLC
NCT00907504Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Jul 2010
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of figitumumab in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Planned start Jul 2010; status: withdrawn.
02
Drugs
figitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00907504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00907504.